Clinical trials: CMV Infection
Cytomegalovirus Infection
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV…
- Trial name
- NCT05683457
- Testing
- mRNA-1647
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections
Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults
The purpose of this study is to compare the safety and effectiveness of four different doses of cytomegalovirus vaccines in healthy adults.
- Trial name
- NCT02826798
- Testing
- VBI-1501A 0.5 μg, VBI-1501A 1.0 μg, VBI-1501A 2.0 μg
- Where
- 3 sites in Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Cytomegalovirus Retinitis, HIV Infections
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral…
- Trial name
- NCT00002355
- Testing
- Fomivirsen sodium
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Infection
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seropositive and CMV-seronegative…
- Trial name
- NCT06133010
- Testing
- mRNA-1647
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infections
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
- Trial name
- NCT00411645
- Testing
- maribavir
- Where
- 97 sites in United States, Belgium and 7 more
- Volunteers
- 681 people
- Sponsor
- Shire
SARS-CoV-2, Seasonal Influenza
A Study of Modified mRNA Vaccines in Healthy Adults
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
- Conditions
- SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
- Trial name
- NCT05397223
- Testing
- mRNA-1273, mRNA-1010, mRNA-1345
- Where
- 8 sites in United States
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
CMV
A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of cytomegalovirus (CMV) infection in stem cell transplant…
- Trial name
- NCT01769170
- Testing
- Brincidofovir
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 452 people
- Sponsor
- Jazz Pharmaceuticals
BKV Infection, CMV Infection
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
The goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic…
- Conditions
- BKV Infection, CMV Infection, EBV Infection
- Trial name
- NCT07685457
- Testing
- LB-DTK-MV
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- LucasBio
Prevention of CMV Infection or Disease
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT02137772
- Testing
- Letermovir
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Transplantation, Cytomegalovirus Infections
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients.
- Trial name
- NCT01376804
- Testing
- valganciclovir [Valcyte]
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus (CMV)
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of…
- Trial name
- NCT05319353
- Testing
- Maribavir
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 80 people
- Sponsor
- Takeda
Infections, Cytomegalovirus
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
This will be the first time in humans (FTIH) study with the GSK Bio recombinant gB antigen to evaluate safety and immunogenicity of this CMV candidate vaccine with a proprietary GSK adjuvant system.
- Trial name
- NCT00435396
- Testing
- GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
- Where
- 2 sites in Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Gastrointestinal Diseases
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy.
- Trial name
- NCT00002145
- Testing
- Foscarnet sodium
- Where
- 15 sites in United States
- Volunteers
- 145 people
- Sponsor
- Astra USA
Kidney Diseases, Kidney Injury
ID-ENTITY Trial- Evaluating Serial T-ID Monitoring
To evaluate the association between time-updated CMV and BK viral loads measured monthly by T-ID and the risk of CMV disease and/or biopsy-proven BK virus-associated nephropathy (BKVAN) during the first 12 months following kidney…
- Conditions
- Kidney Diseases, Kidney Injury, BK Virus Infection, CMV
- Trial name
- ID-ENTITY (NCT07393594)
- Testing
- Blood tests, TRAC( cell free DNA) and T-ID
- Where
- 14 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Transplant Genomics, Inc.
Cytomegalovirus (CMV)
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV…
- Trial name
- NCT02931539
- Testing
- Maribavir, Ganciclovir, Valganciclovir
- Where
- 134 sites in United States, Australia and 12 more
- Volunteers
- 352 people
- Sponsor
- Shire
Infections, Cytomegalovirus
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
The purpose of this study is to evaluate the persistence of the vaccine induced immune responses at Month 48 (Year 4) and Month 60 (Year 5) in healthy subjects who received 3 doses of GSK Biologicals' candidate CMV vaccine…
- Trial name
- NCT01357915
- Testing
- Blood sampling, GSK149203A
- Where
- 2 sites in Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus Infections, Cytomegalovirus Retinitis
Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient
To make intravenous (IV) ganciclovir available to immunocompromised patients with life-threatening or sight-threatening Cytomegalovirus (CMV) infection, where the symptoms of the disease are too severe to allow admission to a…
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, HIV Infections
- Trial name
- NCT00002025
- Testing
- Ganciclovir
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus (CMV)
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with…
- Trial name
- NCT01611974
- Testing
- Maribavir
- Where
- 32 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shire
Cytomegalovirus Infection
Maribavir for Prevention of CMV After Stem Cell Transplants
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy.
- Trial name
- NCT00223925
- Testing
- Maribavir
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Shire
Autologous Hematopoietic Stem Cell Transplant
Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.
The goal of this clinical study is to evaluate the safety of cytokine-induced-killer (CIK) cells during early transplant period of autologous hematopoietic stem cell transplant.
- Trial name
- NCT07692607
- Testing
- CIK cells
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- LucasBio